Stem cell donation for transplant is, in almost every case, an unpaid act. Registries worldwide operate on the principle that donating blood-forming stem cells to a stranger is altruistic, and most countries either prohibit or strongly discourage direct payment to donors. That said, the picture is more complicated than a flat “no.” Donors typically receive reimbursement for certain out-of-pocket costs, a U.S. court ruling opened a narrow legal door to compensation for one collection method, and an entirely separate category of stem cell donation for research does sometimes involve payment.
Why Stem Cell Registries Do Not Pay Donors
The World Marrow Donor Association, which sets standards for unrelated donor registries around the globe, has long held that hematopoietic (blood-forming) stem cell donation should remain unpaid. Their position is not arbitrary. The WMDA has outlined several concerns: that paying donors could coerce economically vulnerable people into taking on medical risk they would otherwise decline, that it could undermine the broader culture of voluntary donation, and that it could compromise the international exchange of stem cells by creating disparities between wealthy and less-wealthy countries’ registries.
The WMDA also argues that paying donors could paradoxically harm patients. If donation becomes a commercial transaction, there is a risk that some donors might conceal health information that would normally disqualify them, motivated by the prospect of a payout. That could reduce the quality and safety of the donated cells. Registries like Be The Match in the United States, Anthony Nolan in the United Kingdom, and the German DKMS all follow this unpaid model.
What Donors Actually Receive
Saying donation is “unpaid” does not mean donors absorb every cost. Most registries reimburse donors for travel, lodging, meals, and lost wages associated with medical appointments, pre-donation testing, and the donation itself. In the United States, Be The Match covers these costs and provides short-term medical insurance that applies to any complications arising from the donation. In some countries, employers are encouraged or legally required to grant paid leave for donation-related absences.
The distinction matters: reimbursement replaces money you spent or income you lost. It is not a fee for your cells. This line can feel thin in practice, especially for a donor who takes a week off work and receives wage replacement, but ethically and legally it is the difference between compensating someone for their sacrifice and putting a price tag on human tissue.
The Flynn v. Holder Exception
In the United States, the National Organ Transplant Act of 1984 makes it a federal crime to buy or sell human organs, and bone marrow was historically included under that ban. But in 2011, a Ninth Circuit Court ruling in the case Flynn v. Holder changed the legal landscape for one specific collection method. The court held that donors could receive compensation for peripheral blood stem cell (PBSC) donations, the method where stem cells are collected from the bloodstream through an apheresis machine rather than extracted directly from the bone.
The reasoning was that PBSC collection more closely resembles a blood draw than a surgical bone marrow harvest, and blood products have always been exempt from the organ sale prohibition. The ruling applied within the Ninth Circuit’s jurisdiction (covering several western U.S. states), and while it has not been tested nationally, it opened a legal pathway that did not exist before.
In practice, this ruling has not led to widespread paid stem cell donation. Major registries still operate on the altruistic model, and no large-scale commercial marketplace for PBSC donations has emerged. The case was brought partly as a thought experiment about whether financial incentives could expand the donor pool, particularly for patients from underrepresented ethnic backgrounds who struggle to find matches. Whether payment would actually boost registration rates remains debated. The WMDA responded to the legal challenge by reaffirming its stance that donors should not be paid, citing the risks already described.
What the Donation Process Looks Like
Understanding the physical commitment involved in stem cell donation helps explain why compensation is even a question. There are two main collection methods, and which one you undergo depends on the patient’s medical needs and, to some extent, your own preference.
The older method is a bone marrow harvest, a surgical procedure done under general anesthesia. A doctor uses a needle to withdraw liquid marrow from the back of your pelvic bones. It typically takes one to two hours, and most donors go home the same day or the next morning. Recovery varies, but a study of healthy donors found that about three-quarters resumed basic daily activities like walking, eating, and reading within 12 hours of the procedure. Soreness at the needle sites and fatigue can linger for a week or two, and some donors report feeling drained for longer depending on how much their hemoglobin dropped.
The more common method today is PBSC collection, the apheresis-based approach at the center of the Flynn v. Holder case. For several days before the collection, you receive injections of a drug called filgrastim (a form of G-CSF) that stimulates your bone marrow to push extra stem cells into your bloodstream. On collection day, you sit in a chair while blood is drawn from one arm, run through a machine that separates out the stem cells, and returned through the other arm. The whole session takes four to six hours and sometimes needs to be repeated the next day.
Safety and Side Effects
Both collection methods carry real but generally manageable risks. During the filgrastim injections before PBSC donation, the most common complaints are bone pain, headaches, and fatigue, which makes sense because the drug is forcing your marrow into overdrive. A ten-year follow-up study of healthy donors who received filgrastim found that about 95% experienced at least one side effect during the mobilization period, but no permanent changes in physical or mental health were detected over the full decade of monitoring. Younger donors tended to report fewer problems, and women reported roughly twice the rate of side effects as men.
The rare but serious complication that gets the most attention is splenic rupture. Filgrastim causes the spleen to enlarge slightly as it processes the flood of new blood cells, and in very uncommon cases, the spleen can tear. Case reports have documented this happening even in otherwise healthy donors. One published case described a 40-year-old woman who developed sharp abdominal pain on her fourth day of filgrastim injections; imaging confirmed a ruptured spleen. While this outcome is uncommon enough that it should not discourage donation, it underscores that this is a real medical procedure with real stakes, not a trivial blood draw.
For bone marrow harvest, the primary risks are those of any procedure involving general anesthesia, plus localized pain and the possibility of infection at the puncture sites. Donors with lower baseline hemoglobin tend to recover more slowly, because the volume of marrow withdrawn temporarily drops their red blood cell count further.
How Registries Screen Donors
Before any of this happens, potential donors go through a thorough medical evaluation. The WMDA recommends detailed screening that includes a review of the donor’s medical history, assessment of infectious disease risk, and identification of conditions that might make donation unsafe for the donor or the recipient. Some conditions lead to permanent deferral from the registry; others result in temporary holds.
This screening is partly why registries resist the idea of payment. A system where people are financially motivated to donate creates an incentive to minimize or hide health problems during screening. In blood banking, where donors are sometimes compensated, this tension has been studied extensively, and it is one reason many countries moved toward fully voluntary, unpaid blood donation decades ago. Stem cell registries learned from that history.
Egg Donation for Stem Cell Research
There is a completely different category of “stem cell donation” where payment is not only allowed but actively debated: donating eggs (oocytes) for stem cell research. Scientists studying embryonic stem cells or developing therapeutic cloning techniques sometimes need fresh human eggs, and obtaining them from willing donors has proven difficult without financial incentives.
Research has found that women are largely unwilling to donate eggs for research on an altruistic basis, and the reluctance appears to stem more from the absence of payment than from ethical objections to the science itself. This has led to calls from researchers to shift the conversation from whether to pay egg donors to how much payment is appropriate.
One program in the United States reported outcomes from what was described as the largest compensated egg donation program for stem cell research in the country, possibly worldwide. Donors in that program said they were motivated primarily by compensation and a desire to help others, and they generally reported a favorable experience. The existence of such programs highlights the contrast with the transplant world: in research settings, the ethical calculus around payment plays out differently, partly because the eggs are not going to a specific patient in a life-threatening situation, and partly because egg retrieval is a more invasive process than a blood draw, involving hormonal stimulation and a surgical procedure.
Cord Blood Banking and Its Costs
Another area that blurs the line between “donating” and “paying” is umbilical cord blood, which is rich in stem cells and can be used for transplants. Parents can choose to donate their newborn’s cord blood to a public bank at no cost, making it available for any patient who needs it. Alternatively, they can pay a private cord blood bank to store it exclusively for their family’s potential future use.
Private banking comes with an up-front collection and processing fee plus an annual storage charge, and these costs add up over the years. Over the past two decades, private banks have grown rapidly, storing an estimated four million cord blood units worldwide for individual families. Public cord blood banking, meanwhile, also carries a significant financial burden for health systems, since the infrastructure for collection, processing, testing, and long-term storage is expensive to maintain.
Neither of these scenarios involves “getting paid” in the way most people mean when they ask the question. If you donate cord blood to a public bank, you receive nothing. If you bank it privately, you are the one paying. The practical takeaway for expecting parents is that public donation is a genuinely altruistic act that costs you nothing and could save a stranger’s life, while private banking is an insurance policy with uncertain odds of ever being needed.
How International Rules Differ
The no-payment norm for transplant donation is global but not perfectly uniform. The WMDA’s standards are followed by member registries in dozens of countries, but what counts as “reimbursement” versus “compensation” varies. In some countries, reimbursement is calculated generously enough that it could function as a financial incentive for lower-income donors; in others, it barely covers taxi fare. A few countries allow modest “thank you” payments or gifts that technically fall outside the category of reimbursement but serve a similar motivational purpose.
The WMDA has expressed concern that any move toward paying donors in one country could create a domino effect. International stem cell exchange depends on a shared ethical framework. If the U.S. were to broadly legalize donor payment, registries in countries where payment is prohibited might refuse to share cells with American transplant centers, or vice versa. The result could fragment a system that currently enables a patient in Japan to receive cells from a donor in Germany with relatively little friction. This interconnectedness is one of the strongest practical arguments the WMDA offers for maintaining the unpaid standard.
The Gap Between Donors Needed and Donors Available
Underlying the entire payment debate is a supply problem. Millions of people are registered as potential stem cell donors worldwide, but finding a match for any given patient depends on shared genetic markers that vary by ethnicity. Patients from minority ethnic backgrounds face significantly longer odds of finding a well-matched unrelated donor, because fewer people from those groups are on the registries.
Proponents of donor compensation argue that financial incentives could help close this gap by attracting registrants who would not otherwise sign up. The counterargument, as the WMDA and others have articulated, is that money might bring in the wrong kind of motivation, attracting people who are less committed and more likely to back out when they learn what donation actually involves. Dropout rates after a match is found are already a problem in the current system; the fear is that paid registrants would make it worse.
There is also a subtler concern. If donation becomes a paid transaction, the social meaning changes. People who currently donate because it feels like a profound act of solidarity might view it differently if the person in the next chair is doing it for a check. Whether that cultural shift would actually reduce altruistic donation or is simply a paternalistic worry remains an open question, but it is one that registries take seriously.
Expenses That Catch Donors Off Guard
Even with reimbursement programs, some donors end up absorbing costs they did not anticipate. Self-employed donors may find that lost-income documentation is harder to produce than it would be for a salaried employee, and some registries cap reimbursement at levels that do not fully cover high earners’ lost wages. Childcare costs during medical appointments and recovery days are not always covered. In countries without strong employment protections for donors, taking time off work can create friction with employers, even if it does not lead to outright financial loss.
For the bone marrow harvest method specifically, recovery can occasionally stretch beyond the anticipated week or two, especially if complications arise. The donor insurance provided by programs like Be The Match is meant to cover medical costs related to the donation, but navigating insurance claims while recovering is an added stressor that unpaid donors did not sign up to manage. These practical realities contribute to the argument that the current “reimbursement only” model, while ethically sound, places a disproportionate burden on donors who are already giving something irreplaceable.